Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Marsha K. Leith"'
Autor:
Asher Begleiter, Nadia El-Gabalawy, Laurie Lange, Marsha K. Leith, Lynn J. Guziec, Frank S. Guziec Jr
Publikováno v:
Drug Target Insights, Vol 2009, Iss 4, Pp 1-8 (2009)
NQO1 (NAD(P)H:quinoneoxidoreductase 1) is a reductive enzyme that is an important activator of bioreductive antitumor agents. NQO1 activity varies in individual tumors but is generally higher in tumor cells than in normal cells. NQO1 has been used as
Externí odkaz:
https://doaj.org/article/69737853a199495b94c1ec8fd990296c
Autor:
Asher Begleiter, Nadia El-Gabalawy, Laurie Lange, Marsha K. Leith, Lynn J. Guziec, Frank S. Guziec Jr
Publikováno v:
Drug Target Insights, Vol 4, Iss 1 (2009)
Abstract non disponibile
Externí odkaz:
https://doaj.org/article/0f861a75747f4c1f97dc85726c56b6f0
Autor:
Asher Begleiter, Nadia El-Gabalawy, Laurie Lange, Marsha K. Leith, Lynn J. Guziec, Frank S. Guziec
Publikováno v:
Drug Target Insights, Vol 4 (2009)
NQO1 (NAD(P)H:quinoneoxidoreductase 1) is a reductive enzyme that is an important activator of bioreductive antitumor agents. NQO1 activity varies in individual tumors but is generally higher in tumor cells than in normal cells. NQO1 has been used as
Externí odkaz:
https://doaj.org/article/86a00a54cb304a71b831e26a879caa3f
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:713-723
RH1 is a new bioreductive agent that is an excellent substrate for the two-electron reducing enzyme, NAD(P)H quinone oxidoreductase 1 (NQO1). RH1 may be an effective NQO1-directed antitumor agent for treatment of cancer cells having elevated NQO1 act
Publikováno v:
Cancer Chemotherapy and Pharmacology. 56:307-316
NQO1 is a reductive enzyme that is important for the activation of many bioreductive agents and is a target for an enzyme-directed approach to cancer therapy. It can be selectively induced in many tumor types by a number of compounds including dimeth
Publikováno v:
British Journal of Cancer
The bioreductive antitumour agent, mitomycin C (MMC), requires activation by reductive enzymes like NAD(P)H:quinone oxidoreductase 1 (NQO1). We used a novel approach to increase MMC efficacy by selectively inducing NQO1 in tumour cells in vivo. CD-1
Publikováno v:
Biochemical Pharmacology. 61:955-964
NAD(P)H:(quinone acceptor)oxidoreductase (DT-diaphorase) is a two-electron reducing enzyme that activates bioreductive antitumor agents and is induced by a wide variety of compounds including 1,2-dithiole-3-thione (D3T). We investigated factors influ
Publikováno v:
British Journal of Cancer
DT-diaphorase is a two-electron-reducing enzyme that is an important activator of bioreductive anti-tumour agents, such as mitomycin C (MMC) and EO9, and is inducible by many compounds, including 1,2-dithiole-3-thiones (D3Ts). We showed previously th
Autor:
Asher Begleiter, Marsha K. Leith
Publikováno v:
Biochemical Pharmacology. 50:1281-1286
Mitomycin C (MMC) is a bioreductive antitumor agent that is activated by NADPH:cytochrome P450 reductase (EC 1.6.2.4) and NAD(P)H:(quinone acceptor) oxidoreductase (EC 1.6.99.2) (DT-diaphorase). DT-diaphorase is a two-electron reducing enzyme that is
Autor:
Frank S. Guziec, Marsha K. Leith, Asher Begleiter, Laurie Lange, Nadia El-Gabalawy, Lynn J. Guziec
Publikováno v:
Drug Target Insights, Vol 4 (2009)
Drug Target Insights
Drug Target Insights
NQO1 (NAD(P)H:quinoneoxidoreductase 1) is a reductive enzyme that is an important activator of bioreductive antitumor agents. NQO1 activity varies in individual tumors but is generally higher in tumor cells than in normal cells. NQO1 has been used as